Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70399 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Lan Peng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis…. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Neoplasm Recurrence, Local, Nasopharyngeal Neoplasms, Immunotherapy. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Patients with recurrent/metastatic nasopharyngeal carcinoma (RM‐NPC) do not yet have a strong recommended regimen after failure of first‐line systemic therapy. This study retrospectively analyzed the efficacy of immunotherapy regimens in RM‐NPC that failed at least first‐line therapy. From February 2014 to August 2023, a total of 794 patients with RM‐NPC were included in this study, of which 75 patients received anti‐programmed cell death protein‐1 (PD‐1) only (P), 130 patients received anti‐PD‐1 plus antiangiogenic therapy (AP), 210 patients received anti‐PD‐1 plus single‐agent chemotherapy (C1P), 276 patients received anti‐PD‐1 plus two‐agent chemotherapy (C2P), and 103 patients received anti‐PD‐1 plus antiangiogenic plus chemotherapy (CAP). Progression‐free survival (PFS), overall survival (OS), and adverse events were analyzed. In the inverse probability of treatment weighting (IPTW) cohort, median follow‐up time was 28.7 months, median PFS in the P, AP, C1P, C2P, and CAP were 3.6, 8.5, 7.6, 12.7, and 16.3 months, respectively. PFS was significantly better in the CAP, C2P, C1P, and AP than P ( p values of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer…
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Nasopharyngeal Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
- Department of Otolaryngology-Head and Neck Surgery, The Fifth Affiliated Hospital of the Medical University of Guangzhou, Guangzhou, China.
- The First Hospital of Nanchang, Nanchang, China.
ORCID-Profile: You-Ping Liu, Ming-Yuan Chen
Förderung
- National Natural Science Foundation of China
- Jiangxi Provincial Natural Science Foundation of China
Zitieren
APA
Peng, L., Ding, X., Zou, R. C., You, R., Liu, Y. P., Liang, J. L., Chen, S. Y., Ouyang, Y. F., Long, G. E., & Chen, M. Y. (2026). Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.70399
Vancouver
Peng L, Ding X, Zou RC, You R, Liu YP, Liang JL, et al. Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma. International Journal of Cancer. 2026. doi:10.1002/ijc.70399
BibTeX
@article{Peng2026,
author = {Peng, Lan and Ding, Xi and Zou, Rui-Chao and You, Rui and Liu, You-Ping and Liang, Jiong-Lin and Chen, Si-Yuan and Ouyang, Yan-Feng and Long, Ge-Er and Chen, Ming-Yuan},
title = {Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70399}
}
EUVIMED